Teleflex (TFX) Tops Q4 EPS by 20c, Revenues Beat; Offers FY21 EPS Outlook

Go back to Teleflex (TFX) Tops Q4 EPS by 20c, Revenues Beat; Offers FY21 EPS Outlook

Teleflex (TFX) Announces Submission of Biologics License Application for Its Investigational Freeze Dried Plasma

February 24, 2021 6:43 AM EST

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational freeze dried plasma (FDP) candidate. The... More